Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Drug Review Approvals Europe

COVID-19 Vaccine Skycovion Among Raft Of New EU Filings

  • News

Executive Summary

EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.

You may also be interested in...



New EU Filings

Givinostat, Italfarmaco’s investigational treatment for Duchenne muscular dystrophy, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

New EU Filings

Zolbetuximab, Astellas’ Claudin 18.2-targeting cancer drug, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

New EU Filings

Fruquintinib, Takeda/Hutchmed’s treatment for adult patients with previously treated metastatic colorectal cancer, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Generics Bulletin
Pink Sheet

Topics

Related Companies

Tags:
Drug Review Approvals Europe
Latest Headlines

Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings

Increase In Subpar Pharmaceutical Repacking Draws US FDA Attention

Regulatory Flexibility: BrainStorm’s Problematic NurOwn BLA May Be A Bridge Too Far For US FDA

And Then There Were 19: NurOwn Adcomm Loses Temporary Voting Member To Last-Minute Recusal

See All
UsernamePublicRestriction

Register

PS146881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By